Drugmaker Incyte falls after downbeat annual revenue forecast

Incyte

10/02/2026 13:31

** Drugmaker Incyte's INCY.O shares fall 5% to $103.62 premarket after weak 2026 revenue forecast

** Forecasts 2026 revenue between $4.77 bln and $4.94 bln, below estimates of $5.52 bln - LSEG-compiled data

** Co flags key growth driver Opzelura will underperform, raising concerns about ability to offset looming patent losses on top-seller Jakafi

** INCY reports Q4 adj. EPS of $1.80 vs analysts' average estimate of $1.93 - LSEG compiled data

** Co's product expenses grow faster than product revenue in Q4

** INCY's R&D expenses increase 37% year-on-year

** Co misses profit estimates for the first time in four quarters - LSEG data

** Q4 revenue, however, beats analysts' estimates on stronger demand for blood-disease drug Jakafi

** INCY stock gained 43% in 2025

 (Reporting by Utkarsh Tushar Hathi)

 ((utkarshtushar.hathi@thomsonreuters.com))